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Culture, Dott. Minafra Luigi, Dott. Bravatà Valentina and Dott. 
Saporito Michele, papers published by our group at IBFM-CNR UOS 
Cefalù and review in international journals and conferences of 
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Abstract 
Osteoarthritis (OA) is a multifactorial, inflammatory and disabling 
degenerative joints disorder characterized by degeneration of 
articular cartilage, intra-articular inflammation with synovitis, and 
changes in peri-articular and subchondral bone. OA involves the 
synovial tissues and articular cartilage, resulting in symptoms that 
cause a decrease in the quality of life and disability. The non-
modifiable risk factors include gender and age whereas the 
modifiable risk factors include body mass index (BMI), 
injury/trauma, among others. 
Genetic studies have opened new opportunities in the definition and 
classification of OA etiopathogenesis describing a multifactorial 
disease that originates from both genetic and environmental factors. 
The main genes whose mutations are associated with the onset of OA 
encode proteins involved in some biological processes: bone 
morphogenesis, thyroid metabolism, apoptosis and mitochondrial 
damage, inflammation and the immune response and the Wnt signal 
cascade. 
To date, OA is incurable and most treatments, which include 
physiotherapy, life-style modifications, pharmacotherapy and 
surgery, aim to provide symptomatic relief rather than targeting the 
disease processes themselves. 
This work represents a multidisciplinary and translational medicine 
approach to study OA where clinical, radiographic, genetic and 
biochemical evaluation could contribute to better define the disease 
grading and progression for the development of new therapies. 
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Introduction and background 
Osteoarthritis (OA) is a multifactorial, inflammatory and disabling 
degenerative joints disorder characterized by degeneration of 
articular cartilage, intra-articular inflammation with synovitis, and 
changes in peri-articular and subchondral bone [1]. OA involves the 
synovial tissues and articular cartilage, resulting in symptoms that 
cause a decrease in the quality of life and disability, representing a 
widespread and chronic disease that affects up to 80% of the 
population over 65 years of age [2]. The non-modifiable risk factors 
include gender and age whereas the modifiable risk factors include 
body mass index (BMI), injury/trauma, among others. 
Among the risk factors, age contributes to a substantially increased 
risk of knee OA onset and progression  [3-6], even if the association 
of age with the progression of knee OA is sometimes conflicting [7]. 
Before 50 years of age, the prevalence of OA in most joints is higher 
in men than in women. After about age 50 years, women are more 
often affected than men [8]. A recent report indicates that knee OA is 
likely to become the fourth most common cause of disability in 
women and the eighth most common cause in men [9].  
To date, OA is incurable and most treatments, which include 
physiotherapy, life-style modifications, pharmacotherapy and 
surgery, aim to provide symptomatic relief rather than targeting the 
disease processes themselves. 
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Epidemiology 
 
OA may develop in any joint, but most commonly affects the knees, 
hips, hands, facet joints and feet.  
The first epidemiological studies on the OA prevalence (number of 
people affected in the population sample) are of autopsy. In 1926, 
Heine has documented a number of 1000 cases with an high presence 
of articular cartilage alterations in people over the age of 65 years. 
(10) In 2005, it was estimated that over 26 million people in the US 
had some form of OA (11). The prevalence of OA, however, varies 
greatly depending on the definition used, age, sex and geographical 
area studied. For example, in Dutch population, the prevalence of 
radiographic osteoarthritis show an increment of rate of the hand, and 
lower of knee and hip Figure 1 (12). The incidence of hand, hip and 
knee OA increases with age, and women have higher rates than men, 
especially after the age of 50 years A levelling off or decline occurs 
at all joint sites around the age of 80 years (13). Another example of 
age, sex and geographic modification of epidemiology is showed 
from the Fallon Community Health Plan in Massachusetts (USA), in 
which incidence rate was highest for knee OA 240/100,000 person-
years, with intermediate rates for hand OA (100/100,000 person-
years) and lowest observed rates for hip OA (88/100,000 person-
years) (Figures 2-3) (13-14). Incidence rates found by the Dutch 
Institute for Public Health (RIVM) in 2000 were of a similar level. 
For hip OA, the reported prevalence was 0.9 and 1.6 per 1000 per 
year in men and women respectively and for knee OA the 
corresponding figures were 1.18 and 2.8 per 1000 per year in men 
and women respectively (10). 
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Figure 1: Prevalence of OA in a Dutch population cohort 
 
 
 
 
 
Figure 2: Incidence of Symptomathic OA : Fallon Health plan 
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Figure 3:Trend in primary TKA rates from 1991 to 2006 in UK 
 
 
We can assume that in most epidemiological studies is well 
established as OA increases with age and in relation to sex: before 50 
years of age, the prevalence of the disease is highest in man, on the 
contrary after 50 years, with interest of hand, foot, knee, spine and 
hip, is higher in women (TABLE 1) (14-17). Osteoarthritis, along 
with heart disease and cancer, is ultimately one of the typical 
ailments of old age and the second cause of incapacity for work after 
ischemic heart disease (18). 
 
 
Table 1: Epidemiological studies of the incidence of OA 
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Risk	  Factor	  
	  
Risk factor for OA development in current knowledge are classified  
into two fundamental mechanisms related either to the adverse 
effects of ‘‘abnormal’’ loading on normal cartilage or of ‘‘normal’’ 
loading on ‘‘abnormal’’ cartilage. 
The first category comprises of mechanical factors, such as trauma 
and microtrauma, overweight, load deviation, periarticular structures 
alteration (ligaments, menisci), joint incongruity for congenital or 
acquired pathology (dysplasia, slipped capital femoral epiphysis, 
osteonecrosis). The second group includes factors such as aging, 
gender, genetic alterations, metabolic diseases, endocrine 
(acromegaly) and lifestyle (smoking and alcohol). Aging has been 
suggested as the primary factor contributing to this ‘‘abnormal’’ state 
of articular cartilage, although genetic factors causing disruption of 
chondrocyte differentiation and function and influence the 
composition and structure of the cartilage matrix also contribute to 
abnormal biomechanics, independent of the influence of the aging 
process. Aged articular cartilage presents alterations such as 
fibrillation and dehydration, that are signs of the altered response of 
chondrocytes in to the presence of cytokines and other products of 
matrix degradation, inducing the production of pro-inflammatory 
mediators (19) (Figure 4) 
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Figure 4: Chondrocytes response to mechanical force, cytokines and 
matrix degradation product 
 
Different studies have consistently shown a link between overweight 
or obesity and knee OA. Data from the first National Health and 
Nutrition Examination Survey (HANES I) indicated that obese 
women had nearly 4 times the risk of knee OA as compared with 
non-obese women; for obese men, the risk was nearly 5 times 
greater. In a study from Framingham MA, overweight individuals in 
their thirties who did not have knee OA were at greater risk of later 
developing the disease. Other investigations, which performed 
repeated x-rays over time also, have found that being overweight 
significantly increases the risk of developing knee OA. It is estimated 
that persons in the highest quintile of body weight have up to 10 
times the risk of knee OA than those in the lowest quintile. (20-24)  
Metabolic diseases such as hemochromatosis, alkaptonuria or 
ochronosis, Wilson's disease, Gaucher disease are involved in 
chondrocytes damage and increased deposits in the cartilage matrix 
with increased risk of secondary OA.  
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A defect in load axis, valgus or varus knee for example (Figure 5), is 
an important risk factor that aggravates OA due to the degeneration 
of the supporting structures of the joint. 
 
 
 
Figure 5.   Determination of valgus or varus knee 
 
Recently, genetic studies have opened new opportunities in the 
definition and classification of OA etiopathogenesis describing a 
multifactorial disease that originates from both genetic and 
environmental factors  (25-26) . The main genes whose mutations are 
associated with the onset of OA encode proteins involved in some 
biological processes: bone morphogenesis (tgf-β, smad, bmp, GDF5), 
thyroid metabolism (DIO2), apoptosis and mitochondrial damage 
(anp32A), inflammation and the immune response (IL6, IL1, IL10, 
PTGS2, pla2GA4, DQB1) and the Wnt signal cascade (frzb, LRP5). 
Also, have been described mutations associated to the onset of OA of 
some genes encoding components of the extracellular matrix 
(COL2A1, col10A1, col6A4, dvwa) and other genes (ESR1, edg2, kl, 
pitx1, CALM1, CALM2, ace, crush, lep) (27) 
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Genetic studies of patients with OA can help to unravel the molecular 
mechanisms responsible for specific disease manifestations, 
including joint damage, nociception and chronic pain (28) 
 
 
	  
OA	  Pathophysiology	  
The dynamic equilibrium between the on going formation and 
breakdown of the cartilaginous matrix is regulated by an interplay of 
anabolic influences (e.g., insulin-like growth factors [IGF] I and II) 
and catabolic influences (e.g., interleukin-1, tumor necrosis factor 
[TNF] alpha, and proteinases). To a limited extent, these mechanisms 
can eliminate or compensate for the harmful influences that cause 
osteo- arthritis by stimulating and modifying the metabolic activity of 
chondrocytes. When these harmful influences exceed the system’s 
ability to compensate, however, matrix degradation occurs; this is the 
first step in the development of osteoarthritis, which can progress to 
advanced disease (29) (Figure 6).  
 
 
Figure 6: Scheme of events involved in the initiation of OA and 
progression to late stage OA 
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Mechanical and enzymatic factors are thought to impair chondrocyte 
function and damage the matrix  
These events are followed by inflammatory phenomena of synovium  
with increased production of inflammatory cytokines within the joint. 
Subsequently manifests fibrillation and erosion of the cartilage with 
involvement of the subchondral bone tissue and consequent sclerosis 
Besides the subchondral osteosclerosis, spherical cavities are formed 
called geodes or subchondral cyst. Geodes are cystic formations that 
occur around joints in a variety of disorders (including, in addition to 
OA, rheumatoid arthritis, calcium pyrophosphate dihydrate crystal 
deposition disease (CPPD) and avascular necrosis). Presumably, one 
method of geode formation takes place when synovial fluid is forced 
into the subchondral bone, causing a cystic collection of joint fluid. 
(Figure 7) 
 
Figure 7: OA  Pathogenesis 
 
 
 
 14 
 At the edge of the joint, osteochondral tissue abnormal proliferates 
with the formation of osteophytes, recognizable during the 
radiographic examination. 
The synovial membrane shows hypertrophic, with different 
mononuclear cell infiltrates; rarely it is found chondroid metaplasia 
and calcified areas. The joint capsule and ligaments are often fibrotic, 
thickened and retracted as a result of metabolic changes and 
mechanical properties (stiffness) of the degenerative process. (Figure 
8 -9) 
 
 
Figure 8  The healthy and osteoarthritic joint  
(Hunter et al. Osteoarthritis; BMJ 2011)  
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Figure 9: Intraoperative photo of late OA Joint  
(Thanks to Dott. Boniforti and Dott. Saporito) 
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Clinical and radiological assessment of 
Knee OA 
 
All the three compartments of the knee joint can be affected by OA: 
the medial femoral tibial, lateral femur tibial and femoral patellar. 
The medial compartment is most frequently involved (75%) while 
the lateral is often associated with the femur patellar, is less frequent 
(25%). 
Clinical symptoms and signs can be ascertained by patient history, 
physical examination and by self-completed questionnaire.  
The pain typically occurs during loading and it is particularly 
accentuated during the walk up the hill, to come down and go up the 
stairs, in getting up from sitting.  
In early OA, pain can relieve with rest, while in late OA pain is 
continuous and intense and may progress to chronic. Pain is mainly 
localized in the medial compartment and results in a reduction of the 
movement, that represent the most frequent symptom of OA 
The reduction of the movement is often presented in the morning for 
about 30 minutes, but it can also appear as a result of activities during 
the day, making the symptom disabling as much as the pain (30).  
During the physical examination are found palpable bone deformity, 
usually at the level of the medial femoral condyle, and crepitus of  
joints during passive movement. Swelling and joint effusion may be 
present without heat or skin rash ( 31).  
The range of motion in the early stages of the disease may be 
complete but can evolve negatively causing the joint lockout. 
Moreover, it is frequent the deviation of the load, with deformities in 
valgus or varus (Figure 10 -11) 
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Figure 10 Clinical varus knee OA 
 
 
Figure 11 Radiographic valgus knee OA 
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Resuming, a diagnosis of OA is mainly based on symptoms. A 
patient that has reached a certain age and has joint pain, limitation of 
movement, crepitus and, sometimes, effusion in the joint might get 
the diagnosis of OA. Recommendations for the diagnosis of knee OA 
were published in 2010. (32) They include three main symptoms: 
knee pain, short-lived morning stiffness, and functional limitation in 
combination with three signs on physical examination (crepitus, 
restricted movement and bony enlargement).  
The clinical evaluation may be performed before surgery using the 
AKSS, which includes two subscores: knee score (KS) and function 
score (FS). Each subscore ranges from 0 to 100 points. For KS 
evaluation, pain, range of motion, anterior–posterior and mediolateral 
stability, flexion contracture, leg extension and varus–valgus 
alignment were investigated. FS evaluates knee function from a 
patient’s point of view, describing walking ability, climbing stairs 
ability and the use of walking aids.  
For OA radiological X-ray images are the gold standard to confirm 
the clinical diagnosis and to grade the disease (33-35).  
The Kellgren and Lawrence (K&L) classification criteria are the 
most widely used radiographic classification criteria to identify and 
grade OA.	   K&L is performed on anteroposterior and lateral X-ray 
views of the knee, and includes five grades: grade 0, absence of OA, 
grade 1, possible narrowing of joint space and possible presence of 
osteophytes; grade 2, definite narrowing of joint space and definite 
osteophytes; grade 3, definite narrowing of joint space, multiple 
osteophytes, sclerosis, cysts and possible deformity of bone contour; 
and grade 4, marked narrowing of joint space, large osteophytes, 
severe sclerosis, cysts and definite deformity of bone contour (35-36) 
(Table 2  Figure 12) 
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Kellgren - Lawrence classification of Knee Joint OA 
Grade Criteria 
0 Normal 
I Doubtfull narrowing of Joint space, possible 
osteophyte development 
II Definite osteophytes, absent or questionable narrowing 
of joint space 
III Moderate osteophytes, definite narrowing, some 
sclerosis, possible joint deformity 
IV Large osteophytes, marked narrowing, severe sclerosis, 
definite joint deformity 
Table 2 Kellgren & Lawrence grading 
 
 
Figure 12. Radiographic representation of K&L scale    (37) 
 
 
A critical point for OA diagnosis is to identify an early onset and an 
early progression of this disease. Many studies analyse the 
correlation between knee OA radiographic data and clinical status of 
the affected joint by using specific clinical scores and radiographic 
grading scales. 
Despite the advent of newer imaging technologies such as MRI, 
radiological classification will probably remain the diagnostic gold 
standard for knee OA in large epidemiological studies for many 
years to come.  
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OA Single Nucleotide Polymorphisms 
Nowadays, molecular genetic investigations have gained an 
increasingly significant role in the knowledge of OA etiology and 
have provided evidence for a genetic component to OA (38-40). 
Single nucleotide polymorphisms (SNPs) are now introduced as risk 
factors for human disease, thanks to completion of large genome-
wide association studies. . Several gene association analyses, either 
genome wide or a gene candidate approach, identified different genes 
related to the OA susceptibility, onset and progression. OA may thus 
be placed into the category of polygenic diseases  (41-43). Several 
association studies between SNPs and OA disease remain 
unconfirmed or controversial, and it is necessary further research in 
order to contribute to the etiopathogenesis, to better understand 
functional influence of specific SNPs on OA.   
The main bias that may occur in research projects on OA are in  
patient enrolling criteria, differences in OA-affected joint sites, in the 
radiographic evaluation scales used and in subjective differences in 
patient’s pain evaluation scoring, in classification and staging modes. 
Furthermore, the geographical and ethnic allele distribution become 
of interest, and is extremely important in fully understanding the SNP 
variant effects. 
In the Online Mendelian Inheritance in Man database – which 
collects known genetic lesions responsible for human inherited 
diseases – the following principal loci of osteoarthritis susceptibility 
(OS) and the associated polymorphisms, SNPs and aspartic acid (D) 
repeats, are reported: frizzled-related protein (FRZB) rs288326 
(OS1A) and rs7775 (OS1B), MATN3 rs77245812 (OS2), ASPN D14 
repeats (OS3), parathyroid hormone 2 (PTHR2) rs76758470 (OS4), 
growth and differentiation factor 5 (GDF5) rs143383 (OS5) and 
DVWA rs11718863 (OS6). 
In particular, the FRZB gene is a member of a family of the soluble 
Wingless (Wnt) antagonist, codes for “secreted frizzled-related 
protein 3” (sFRP3). Recent evidence has demonstrated that products 
 
 
 21 
of Wnt and Frizzled play a key role in the development and 
maintenance of bones and joints. The rs7775 and rs288326 FRZB 
SNPs variants showed an increased frequency in subjects with 
generalized radiographic OA, as confirmed by other studies in 
Caucasian individuals (44 - 45)  
Articular cartilage is composed of specialized cells, the chondrocytes, 
that produce a large amount of extracellular matrix composed of 
collagen fibres. MATN3 encodes a noncollagenous extracellular 
matrix protein expressed during the development of the skeletal 
system and in the cartilage (46). The matn3 gene codes for matrilin-
3. This protein is found in the extracellular matrix, which is an 
intricate lattice of proteins and other molecules that forms in the 
spaces between cells. Specifically, matrilin-3 is located in the 
extracellular matrix surrounding the cells that make up ligaments and 
tendons, and near cartilage-forming cells (chondrocytes).	   The 
polymorphism Thr303Met (rs 77245812) is associated with OA. 
Another extracellular matrix component deregulated in the articular 
cartilage of OA patients is asporin protein, member of the small 
leucine-rich proteoglycan family, encoded by the ASPN gene and 
expressed at high levels in knee and hip cartilage of individuals with 
ASPN D14 repeats (47). The encoded protein may regulate 
chondrogenesis by inhibiting transforming growth factor-beta 1-
induced gene expression in cartilage. This protein also binds collagen 
and calcium and may induce collagen mineralization. Polymorphisms 
in the aspartic acid repeat region of this gene are associated with a 
susceptibility to osteoarthritis. Alternate splicing result in multiple 
transcript variants. 
The pthr2 gene encodes for a member of the G-protein coupled 
receptor family 2. Its functional role in OA is based on the 
observation that PTHR2 is expressed in a number of endocrine cell 
types and regulates pituitary hormone secretion and specifically 
growth hormone (48).  This protein is expressed in different tissues 
and involved in the regulation of growth hormone secretion, 
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Ca2+homeostasis and, modulation of growth cartilage in condrocytes. 
The polimorphism Leu159Phe (rs76758470) is associated to OA. 
The gdf5 gene encodes for a protein closely related to the bone 
morphogenetic protein (BMP) family, a member of the TGF-beta 
superfamily. Growth differentiation factor 5 has a role in skeletal and 
joint development. Mutations in GDF5 are involved in several  
disorders of skeletal development and also in hip and knee OA 
progression (49-51). The polimorphism rs143383 is associated to 
OA. 
Finally, the DVWA gene, which encodes for a protein containing two 
von Willebrand A domains, was found to harbour the rs11718863 
SNP, showing a consistent association with knee OA in Japanese 
and Chinese OA cohorts (52). The experimental data provided in 
different studies led to the suggestion of a mechanism for the 
etiology of the disease, based on an interaction between DVWA 
protein and beta-tubulin. Two polimorphism, Cys260Tyr (rs7639618) 
and Tyr169Asn (rs 11718863) are indicated as susceptibility loci for 
OA. 
 
 
OA Treatment 
OA is incurable and most treatments, which include physiotherapy, 
life-style modifications, pharmacotherapy and surgery, aim to 
provide symptomatic relief rather than targeting the disease processes 
themselves. Mechanisms by which OA arises and progresses are not 
completely understood (53). The main objective of research is to 
discover new treatment to alleviate the signs and symptoms of the 
disease and to slow its progression. The best OA treatment is 
prevention, as declared in 1966 by Mohing W et al. ( 54).  
There are different therapeutic modalities, from physiotherapy, 
orthopedic aids and orthoses, pharmacotherapy, and finally surgery 
and rehabilitation.  
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According to patient’s symptoms, physical and radiological findings 
surgery is indicated as ultimate treatments. 
It’s possible classify treatment in three different modality of 
intervention: conservative, joint preserving surgical treatment and 
joint replacement surgery (55). 
Conservative treatment are indicated  depending on the severity and 
distribution of symptoms as well as any possible accompanying 
illnesses. The objective are:  
1. Pain relief 
2. Improved quality of life 
3. Improved mobility 
4. Improved walking 
5. Delayed progression of osteoarthritis 
 
Whitin the conservative treatments there are general measures that 
include patient education, lifestyle adjustment, and weight loss. Any 
factors placing excessive and damaging stress on the knee joint 
should be eliminated. Physiotherapeutic measures for knee 
osteoarthritis includes exercise therapy and physical measures, as 
ultrasound application, electrotherapy, muscle stimulation, 
application of heat and cold, massage, acupuncture, 
stretching/walking and traction exercises. Orthopedic aids include 
cushioned heels and wedges correcting the axis to a certain extent 
and taking mechanical stress off the affected part of the joint.  
When signs of inflammation arise, medications are currently used to 
treat knee osteoarthritis. The most suitable type are analgesics/anti-
inflammatory agents, glucocorticoids, opioids, slow-acting drugs for 
OA, and anti-cytokines. 
The next step in the therapeutic scheme is the joint preserving 
surgical treatment. Surgery is indicated only when all 
abovementioned measures have been tried without success and 
considering also patients with advanced osteoarthritis. 
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The overwhelming majority of intra-articular operations are 
performed through an arthroscope.  It’s possible classified joint-
preserving surgical option in three classes: Symptomatic, including 
lavage, shaving and debridement; Bone-stimulating, including 
drilling, microfracturing and abrasion arthroplasty; Joint surface 
restoration with Autologous chondrocyte transplantation (ACT) or  
Autologous osteochondral transplantation (OCT). 
The purpose of Arthroscopic lavage is to rid the joint of detritus and 
inflammatory mediators. Shaving, or chondroplasty, involves remov- 
ing frayed and fragmented cartilage. Debridement is described as 
“house-cleaning arthroplasty,” serves the same general purposes.  
The goal of bone-stimulating techniques is to bring pluripotential 
stem cells to the joint surface, where they are able to form fiber 
bundles take advantage of mechanical and biological forces.  
In ACT, cartilage cells are taken from the joint, cultured ex vivo and 
then put back into the joint. In OCT, also termed mosaicplasty, 
cylinders of cartilage and bone are taken from a part of the non 
affected joint, and subsequently inserted into the cartilage defect. The 
reported results of ACT and OCT are very promising.  
Last step in therapeutic treatment is joint surgery, that may be carried 
out by partial joint replacement, one or two compartment, or total 
replacement of three compartment.  
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PhD dissertation 
 
Purpose 
The purpose of this study is to highlight possible associations 
between KL grade, clinical features (AKSS - American Knee Society 
Score, age) and the abovementioned genetic polymorphisms in order 
to update the knee OA grading and to improve a personalized 
treatment program in the future.   
Although several studies described the association between these 
specific polymorphisms and susceptibility to OA, no studies have 
examined their simultaneous presence in OA patients, especially in 
the European people groups.  
Precisely, Sicilian individuals have a specific genetic background and 
different allele distribution compared with the rest of Europe and 
with the rest of Italy (north–south genetic trend), due to distinct 
gene–environment interactions and, certainly, due to deep human 
migration movements, which have occurred in Sicily over the 
centuries as described by several authors (56-58) 
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Methods 
Patients 
On admission to hospital, 66 Sicilian patients affected by primary 
OA, aged 54 to 86 years, candidates for knee surgery of arthroscopy 
or arthroplasty, were enrolled in this project. The patients were 
grouped, according to age, into two groups: young (from 54 to 65 
years old) and old (from 66 to 86 years old). Among these, 61 
patients were selected for genotyping analysis due to availability of a 
blood sample and for cytokines study. This study (named 
OA_BIOMOL_1) was approved by the Ethical Committee of the San 
Raffaele G. Giglio Hospital, Cefalù, Italy (number of protocol: CE 
2011/63) and the patients gave their written informed consent 
according to the Helsinki Declaration (Figure 13). 
 
For each patient, it has designed a data collection sheet in which we 
considered: 
- Number, age and sex of the patient; 
- weight and height (to calculate Body Mass Index - BMI) 
- Knee examined (right or left); 
- Degree of OA of K & L (0 to 4) and the appropriate class (A, B, C),   
- Knee score and the related class (1, 2, 3, 4) function score  
- Biological samples carried out, executed.  
 
We also enrolled 100 healthy Sicilian subjects as control samples for 
mutational analysis.  
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Figure 13 Data collection sheet  
 
 
 
Clinical evaluation 
The clinical evaluation was performed for each patient before surgery 
using the AKSS, which includes two subscores: knee score (KS) and 
function score (FS). Each subscore ranges from 0 to 100 points. For 
KS evaluation, pain, range of motion, anterior–posterior and 
mediolateral stability, flexion contracture, leg extension and varus–
valgus alignment were investigated. FS evaluates knee function from 
a patient’s point of view, describing walking ability, climbing stairs 
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ability and the use of walking aids. The AKSS was classified into 
three levels for both KS and FS: high (HKS, HFS), medium (MKS, 
MFS) and low (LKS, LFS). The patients with LKS and LFS had 
scores between 0 and 49 points. The patients with MKS and MFS 
had scores between 50 and 69 points. The patients with HKS and 
HFS had scores from 70 to 100. 
 
 
Radiographic evaluation 
The radiographic evaluation was performed on anteroposterior and 
lateral X-ray views of the knee by a single investigator using the KL, 
which includes four grades: grade 1, possible narrowing of joint 
space and possible presence of osteophytes; grade 2, definite 
narrowing of joint space and definite osteophytes; grade 3, definite 
narrowing of joint space, multiple osteophytes, sclerosis, cysts and 
possible deformity of bone contour; and grade 4, marked narrowing 
of joint space, large osteophytes, severe sclerosis, cysts and definite 
deformity of bone contour (35, 59). The evaluation was undertaken 
on an X-ray performed no more than 4 months before surgery. In this 
study, we grouped grade 1 and grade 2 into a single grade because 
the radiographic differences in our cohort were considered not 
relevant compared with those between KL grade 3 and grade 4. The 
KL classification was therefore summarized into three groups: group 
A (grades 1 and 2), group B (grade 3), and group C (grade 4). 
 
 
Genetic analysis 
The patients were genotyped by sequencing analysis, for the 
following genetic polymorphisms associated with OS, SNPs and D 
repeats: FRZB rs288326 (OS1A) and rs7775 (OS1B), MATN3 
rs77245812 (OS2), PTHR2 rs76758470 (OS3), ASPN D14 repeats 
(OS4), GDF5 rs143383 (OS5) and DVWA rs11718863 (OS6). The 
Human Gene Mutation Database and the dbSNP Short Genetic 
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Variations database were used to analyze gene regions containing the 
selected SNPs (60-61). Genomic DNA was extracted from peripheral 
blood using the QIAamp DNA blood mini kit, according to the 
manufacturer’s specifications (Qiagen Inc., Valencia, CA, USA). 
After quality and quantity analysis, DNA was polymerase chain 
reaction amplified using primers designed by the Primer3 software 
(62) and listed in Table 3. Polymerase chain reaction reactions were 
performed with 50 ng genomic DNA in a total volume of 50 µl 
containing 1°— PCR Gold Buffer, 1.5 mM di-MgCl2, 200 µM 
dNTPs, 200 nM forward and reverse primer mix and 1.25 U 
AmpliTaq Gold DNA Polymerase (Life Technologies Monza, MB, 
Italy). The thermal cycle profile employed a 5-minute denaturing step 
at 94°C, followed by 35 cycles at 94°C for 45 seconds, 59°C for 45 
seconds and 72°C for 45 seconds, and a final extension step of 5 
minutes at 72°C. The quality and quantity of polymerase chain 
reaction products were assessed on the Bioanalyzer instrument 
(Agilent Technologies, Santa Clara, CA, USA) and were purified 
using the QIAquick PCR purification kit, according to the 
manufacturer’s specifications (Qiagen Inc., Valencia, CA, USA). 
To perform DNA sequencing, purified amplicons were labelled with 
the BigDye Terminator v3.1 Cycle Sequencing Kit following the 
manufacturer’s standard protocol (Applied Biosystems). The thermal 
cycle profile employed a 1-minute denaturing step at 96°C, followed 
by 25 cycles at 96°C for 10 seconds, 54°C for 5 seconds and 60°C for 
3 minutes. Labelled samples were purified with the Xterminator 
purification kit according to the manufacturer’s standard protocol and 
loaded in a 3500-Dx Genetic Analyzer (Applied Biosystems) for 
separation by capillary electrophoresis. Electropherograms and 
sequence files were analysed using Sequencing Analysis and 
SeqScape software (Applied Biosystems).  
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Primers sequence used for genotyping analysis  
Target gene 
polymorphism  
Forward primer (5°¨ 
to 3°¨)  
Reverse primer (5°¨ 
to 3°¨)  
Template 
size (base 
pairs)  
FRZB 
(rs288326; 
OS1A)  
cctcttggcagcaattggaac  gcccctctcccaagaaaaatg  800 
FRZB 
(rs7775; 
OS1B)  
agggcaggaccttgtctgtt  taagagtctgcccccaaacc  884 
MATN3 
(rs77245812; 
OS2)  
tcacgtcacttcaggctgtg  tggggtctcaccatgttctc  886 
ASPN (D14; 
OS3)  
gcacattgctgaattgctttcca  ctttggggtttgctgtactttc  615 
PTH2R 
(rs144641723; 
OS4)  
tctcgaaccagtccctgct  cccatgacagttgctgtgg  602 
GDF5 
(rs143383; 
OS5)  
gcagatgaattccaggtccag  ccatgaggtggaggtgaaga  818 
DVWA 
(rs11718863; 
OS6A)  
aggctgcctgccattattctt  cccatgctgtttcctttgaaca  924 
Table 3 Primers sequence used for genotyping analysis 
 
 
Synovial fluid sampling and cytokine assay 
With the approval of patients, synovial joint fluid samples were 
collected during knee surgery of arthroscopy or arthroplasty. The 
samples of synovial fluid were immediately stored at – 80°C until 
use. Freeze-thaw cycles were avoided. Key biomarkers of 
inflammation and cytokines quantification was made by Luminex 
technology.  
Before the cytokine assay, SF samples were thawed to room 
temperature (RT) and clarified at 10000g for 10 min. The supernatant 
of each sample was then treated with hyaluronidase (HAse). Each 
sample was prepared and run in duplicates. HAse treatment 
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significantly improved the number of well with good or excellent 
bead events for each bead region (63). The samples were tested for a 
panel of 17 cytokines and chemokines (IL-1b, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17, IFN-c, TNF-a, monocyte 
chemoattractant protein-1 (MCP-1), macrophage inflammatory 
protein-1b (MIP-1b), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), and granulocyte colony-stimulating factor (G-
CSF)) using Bio-plex kit (BioRad, Milan, Italy) and following the 
manufacturer’s instructions. The assay was carried out using the 
Luminex system (BioRad, Munchen, Germany), based on the 
measurement of fluorescent signals released by a suspension of 
microspheres, bringing immobilized multiplex cytokine specific 
antibodies in 96-well plates. The combination of a fluorimetric signal 
of microspheres with that released by a secondary antibody allows us 
to measure cytokine concentration–related signals converted by a 
processor. The assay was performed using an eight-point standard 
curve for every cytokine. Samples were analyzed on a Luminex 100 
device (BioRad), and the data were evaluated using the Bio-Plex 
Manager software (BioRad). Standards, internal controls, and 
samples were reported as means of duplicate measurements. 
 
 
Statistical analysis 
The association between the clinical data (KS, FS, age) and the 
radiographic data (KL) and the association between genotypes and 
KL groups (A, B, C) were analyzed using GraphPad InStat software 
version 3.05 (64). The Mann–Whitney U test, the chi-square test and 
Fisher’s exact test were performed. Differences in groups were 
considered significant when P ≤ 0.05. Hardy–Weinberg equilibrium 
was evaluated. 
The association between DVWA SNPs genotypes and KL groups, 
was analyzed using GraphPad InStat software version 3.05 (San 
Diego California USA). Mann Whitney-U test, Pearson’s Chi-Square 
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test and Fisher’s exact test were performed. Differences in groups 
were considered significant when the p-value was less than or equal 
to 0.05. Hardy-Weinberg Equilibrium (HWE) was calculated. 
Finally, in order to verify the degree of allelic segregation among the 
SNPs of our interest, we calculated the Linkage Disequilibrium (LD) 
coefficients (D’ and r2) using Haploview software 3.32. 
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Results	  
 
Clinical and radiographic evaluation 
We recruited 66 cases (37 females and 29 males), of which 24 were 
young (54 to 65 years) and 42 were old (66–86 years). Subsequently, 
they were divided into three groups (A, B, C) depending on the 
degree of radiographic knee OA. According to the clinical scores we 
classified the patients as follows:  
 
- Group A consisted of 24 patients (11 females and 13 males, 14 
young and 10 old); KS was poor in 13 cases and fair in 11 cases, 
and the average FS score was 51 points.  
- Group B consisted of 21 patients (15 females and six males, eight 
young and 13 old); KS was poor in 19 cases and fair in two cases, 
and the average FS score was 41 points.  
- Group C consisted of 21 patients (11 females and 10 males, two 
young and 19 old); KS was low in all cases, and the average FS 
was 35 points.  
 
Regarding the treatment, 22 patients of group A underwent 
arthroscopy and two patients arthroplasty, two patients of group B 
underwent arthroscopy and 19 patients arthroplasty, and 21 patients 
of group C underwent arthroplasty (Table 4). 
 
Clinical features and treatment for each radiographic group of patients 
KL 
group  
Total  Females  Males  Young  Old  Arthroscopies  Arthroplasties  
A  24 
(36.5%)  
11 
(29.7%)  
13 
(44.8%)  
14 
(58.3%)  
10 
(23.8%)  
22 (91.7%)  2 (4.8%)  
B  21 
(31.8%)  
15 
(40.5%)  
6 
(20.7%)  
8 
(33.3%)  
13 
(30.0%)  
2 (8.3%)  19 (45.2%)  
C  21 
(31.8%)  
11 
(29.7%)  
10 
(34.5%)  
2 
(8.3%)  
19 
(45.2%)  
0 21 (50%)  
 
Table 4 Data presented as number of patients (percentage). KL, 
Kellgren and Lawrence osteoarthritis grading scale. 
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According to the KS and FS scores, the patients in the LKS group 
were in the majority (n = 46), while the 36 patients in the LFS group 
generally had severe symptoms and high disability. There were 19 
patients in the MKS group and 23 patients in the MFS group, and 
thus one third of patients had moderate to severe symptoms and 
disability. One patient was in the HKS group and seven patients were 
in the HFS group, with zero to mild symptoms and disability.  
(Table 5). 
 
Patient classification according to knee score and function score  
KS group  n  %  FS group  n  %  
LKS  46 70 LFS  36 55 
MKS  19 29 MFS  23 35 
HKS  1 2 HFS  7 11 
Table 5 FS, function score (LFS, low; MFS, medium; HFS, high); 
KS, knee score (LKS, low; MKS, medium; HKS, high); n, number of 
patients. 
 
 
 
Association between Kellgren and Lawrence osteoarthritis 
grading and knee score, function score and age. 
Association analyses were performed to verify the possible 
association between clinical data (KS, FS, age) and radiographic data 
(KL). A statistical association between the variables analyzed was 
observed (Table 6). 
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Association between Kellgren and Lawrence osteoarthritis 
grading and knee score, function score and age 
    KL 
score 
    
  Group A Group B Group C P value 
  n      % n      % n      %   
Low knee score 8     33.3 17    81 21    100 <0.0001 
Medium knee score 15    62.5 4    19 0    0 
High knee score 1    4.2  0    0 0    0 
Low function score 8     33.3 13     62 15    71.4 0.022 
Medium function score 10    41.7 7    33.3 6    28.6 
High function score 6    25 1    4.7 0    0 
Age 54 to 65 14    58.3 8    38.1 2    9.5 0.0011 
Age 66 to 86 10    41.7 13    61.9 19    90.5 
 
Table 6 KL, Kellgren and Lawrence osteoarthritis grading scale; n, 
number of patients. *Chi-squared test. 
 
 
Kellgren and Lawrence osteoarthritis grading versus knee score 
In group A, we observed eight patients (33.3%) with LKS, 15 
(62.5%) with MKS and one (4.2%) with HKS. In group B, we 
observed 17 patients (81%) with LKS, four (19%) with MKS and 
none with HKS. In group C, we observed all patients (n = 21) with 
LKS. The highest number of patients with LKS were therefore in 
groups B and C and the radiographic findings are related to clinical 
pictures expressed by the KS score (P = 0.0001). 
 
Kellgren and Lawrence osteoarthritis grading versus 
function score 
In group A, we observed eight patients (33.3%) with LKS, 10 
(41.7%) with MFS and six (25%) with HFS. In group B, we observed 
13 patients (62%) with LFS, seven (33.3%) with MFS and one 
(4.7%) with HFS. In group C, we observed 15 patients (71.4%) with 
LFS, six (28.6%) with MFS and none with HFS. These data show 
that an increase of the OA radiographic severity corresponds to a 
decrease of the function score (P = 0.022). 
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Kellgren and Lawrence osteoarthritis grading versus age 
In group A, we observed 14 young (58.3%) and 10 old (41.7%) 
patients. In group B, we observed eight young (38.1%) and 13 old 
(61.9%) patients. In group C, we observed two young (9.5%) and 19 
old (90.5%) patients. So, it is more common to observe a medium to 
high OA radiographic grade in the population over 65 years old, and 
a low to medium in adults under the age of 65 years old (P = 0.0011). 
 
Mutational analysis of osteoarthritis susceptibility genes 
The OA patients were genotyped for the following polymorphisms 
associated with OS, such as SNPs and D repeats: FRZB rs288326 
and rs7775, MATN3 rs77245812, ASPN D14, PTHR2 rs76758470, 
GDF5 rs143383, and DVWA rs11718863. Percentages of the wild 
type, heterozygote and homozygote genotypes for each 
polymorphism were calculated. We reported genotyping data of the 
three radiographic groups (A, B, C) and the number of individuals for 
each genotype (Table 7). In each group, deviations of Hardy–
Weinberg equilibrium for all polymorphisms analysed were not 
observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 37 
Polymorphism Genotype 
Group 
A       
n=20 
%  HWe Group  B             n=21 %  HWe 
Group C                
n=20 %  HWe 
FRZB                      
(rs288326 - 
OS1A) 
CC WT 17 85   14 66,7   15 75   
CT H 2 10 0,05 7 33,3 0,36 4 20 0,33 
TT MUT 1 5   0 0   1 5   
FRZB                      
(rs7775 - OS1B) 
CC WT 18 90   16 76,2   13 65   
CG H 2 10 0,03 5 23,8 0,54 7 35 0,34 
GG MUT 0 0   0 0   0 0   
MATN3                     
(rs77245812 - 
OS2) 
CC WT 19 95   20 95,2   18 90   
CT H 1 5 0,91 1 4,8 0,91 2 10 0,81 
TT MUT 0 0   0 0   0 0   
ASPN                     
 (D14 - OS3) 
D13 WT 5 25   3 14,3   4 20   
D13/D14 H 11 55 0,65 14 66,7 0,12 11 55 0,65 
D14 MUT 4 20   4 19   5 25   
PTH2R                      
(rs144641723 - 
OS4) 
  
GG WT 19 95   21 100   20 100   
GT H 1 5 0,91 0 0 NA 0 0 NA 
TT MUT 0 0   0 0   0 0   
GDF5 (rs143383 - 
OS5) 
                    
TT WT 3 15   12 57,1   7 35   
TC H 13 65 0,18 5 23,8 0,04 11 55 0,44 
CC MUT 4 20   4 19   2 10   
DVWA 
(rs11718863 - 
OS6) 
                    
TT WT 15 75   17 81   9 45   
TA H 4 20 0,33 4 19 0,63 10 50 0,39 
AA MUT 1 5   0 0   1 5   
HWe: Hardy Weinberg equilibrium * p-value 
 
Table 7 Mutational analysis of osteoarthritis susceptibility genes 
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Kellgren and Lawrence osteoarthritis grading and genotype 
association analysis 
To evaluate a potential association between genotypes, wild-type 
group or mutated (heterozygote and homozygote) group and the KL 
groups (A, B, C), the Mann– Whitney U test, the chi-square test and 
Fisher’s exact test were performed (Table 6). Analysis showed a 
statistically significant association between genotype and KL grade 
for the GDF5 rs143383 and the DVWA rs11718863 polymorphisms 
 (P = 0.02 and P = 0.03, respectively). These results are in line with 
the study of Valdes and colleagues where GDF5 rs143383 and 
DVWA rs11718863 polymorphisms are consistently associated with 
the risk of knee OA in the Caucasian population (65), but to our 
knowledge this is the first study that reports the simultaneous 
presence of these two polymorphisms associated with KL in a 
European group. Unfortunately, concerning the other four OS SNPs, 
no genotype showed any significant association with KL data, as  
revealed by statistical analysis. 
Finally, it is possible to note in Table 8 that the DVWA rs11718863 
polymorphism (genotype heterozygote + homozygote) is more 
represented in group C (55%), compared with the other two groups A 
(25%) and B (19%), suggesting that OS6 can be associated with a 
more severe OA radiographic grade.  
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Polymorphism KL group 
WT                     
n 
WT                                
% 
H+Mut
n 
H+Mut        
% 
*p-
value 
FRZB-OS1A                  
(rs288326)                    
A 17 85 3 15   
B 14 66,7 7 33,3 0,39 
C  15 75 5 25   
FRZB-OS1B                        
(rs7775) 
A 18 90 2 10   
B 16 76,2 5 23,8 0,17 
C  13 65 7 35   
MATN3-OS2                    
(rs77245812) 
A 19 95 1 5   
B 20 95,2 1 4,8 0,75 
C  18 90 2 10   
ASPN-OS3                                  
(D14) 
A 5 25 15 75   
B 3 14,3 18 85,7 0,69 
C  4 20 16 80   
PTH2R-OS4                        
(rs144641723) 
A 19 95 1 5   
B 21 100 0 0 na 
C  20 100 0 0   
GDF5-OS5                       
(rs143383) 
A 3 15 17 85   
B 12 57,1 9 42,9 0,02 
C  7 35 13 65   
DWVA-OS6                       
(rs11718863) 
A 15 75 5 25   
B 17 81 4 19 0,03 
C  9 45 11 55   
NA = not available           
n = number of patients           
*Chi-Squared test           
 
Table 8 Kellgren and Lawrence osteoarthritis grading and genotype 
association analysis 
 
Linkage disequilibrium analysis 
Linkage Disequilibrium (LD) coefficients (D’ and r2) was calculated 
using Haploview software 3.32, in order to verify the degree of 
allelic segregation among the SNPs of our interest. Based on the 
HapMap project databases (66-68), this approach was used for 
rs7639618, rs7639807, rs7651842 by a pairwise tagging mode, 
because allelic frequencies from different populations are available 
on this platform for these three SNPs. Instead, no data were available 
for the other two SNPs, rs17040821 and rs11718863. Then, we 
replicated the D’ and r2 calculation for all the five above-mentioned 
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SNPs, by using the allelic frequencies from our Sicilian cohort of 
healthy subjects, with the proper formulas:  
 
D’ = D/Dmax,  
r2 = D2/ p1p2q1q2 
 
 where, D = (x11)(x22) – (x12)(x21); Dmax is the smaller of p1q2 
and p2q1, where the haplotype frequencies for the hypothetic loci A 
and B are defined as described in the Table 9. For analised Sicilian 
cohort, the pairwise LDs for rs7639618, rs7639807 and rs7651842 
perfectly matched with those observed by Haploview software 
(Table 9).  
Finally, similarly to the Haploview LD output form, it was elaborated 
a r2 LD plot, where the perfect LD between SNPs pair is described 
by r2 = 1 and is dark marked, whereas the LD absence is described 
by r2 = 0 and is white marked (Figure 14).  
 
 
Haplotype  Frequency  Allele  Frequency  
A1B1  x11  A1  p1 =x11 +x12  
A1B2  x12  A2  p2 =x21 +x22  
A2B1  x21  B1  q1 =x11 +x21  
A2B2  x22  B2  q2 =x12 +x22  
Table 9 Linkage disequilibrium analysis 
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Figure 14  r2 LD plot, where the perfect LD between SNPs pair is (r2 
= 1) dark marked, whereas the LD absence (r2 = 0) is white marked 
 
 
Mutational analysis of OA susceptibility genes 
Genotyping analyses were performed by sequencing analysis of 
amplicons of 924 bp, containing the two DVWA SNPs: rs11718863, 
rs7639618. Sequencing analysis of the electropherograms revealed 
the presence of others three less known DVWA SNPs: rs7651842, 
rs7639807 and rs17040821. Sixty-one osteoarthritis patients and one 
hundred healthy subjects were genotyped for the abovementioned 
five DVWA SNPs. Percentages of the wild type (WT), heterozygote 
(H) and homozygote (MUT) genotypes for each polymorphism were 
calculated. SNPs, genotype percentages and allele frequencies of 161 
individuals investigated in this study are also reported (Table 10). For 
OA patients, we reported genotyping data of the three radiographic 
groups (A, B, C) and the number of individuals for each genotype. 
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Deviations of Hardy-Weinberg equilibrium for all polymorphisms 
analyzed were not observed 
(Table 11). 
 
 
	   	   	   	   	   	   	   	  
DVWA	  
polymorhism	  	   Genotype	  	  
OA	  
patients	  
n	  =	  61	  	  
%	  	   Allele	  frequencies	  	   %	  	  
Controls	  
n	  =	  100	  	   %	  	  
Allele	  
frequencies	  	   %	  	  
rs11718863    	  	                 
TT  WT  41 67 T = 100  82 72 72 T = 100  72 
TA  H  18 30 A = 22  18 25 25 A = 56  28 
AA  MUT  2 3     3 3     
rs7639618                    
GG  WT  41 67 G = 100  82 72 72 G = 144  72 
GA  H  18 30 A = 22  18 25 25 A = 56  28 
AA  MUT  2 3     3 3	       
rs7651842                    
AA  WT  44 72,1 A = 103  84,4 85 85 A = 170  85 
AG  H  15 24,6 G = 19  15,6 14 14 G = 30  15 
GG  MUT  2 3,3     1 1     
rs7639807              	  	       
GG  WT  44 72,1 A = 103  84,4 85 85 G = 170  85 
GA  H  15 24,6 G = 19  15,6 14 14 A = 30  15 
AA  MUT  2 3,3     1 1     
rs17040821                    
CC  WT  44 72,1 C = 103  84,4 85 85 C = 170  85 
CT  H  15 24,6 T = 19  15,6 14 14 T = 30  15 
TT  MUT  2 3,3     1 1     
n = number of 
patients.  
                  
 
Table 10 Genetic analysis result 
 
 
 
 
 
 
 
 
 
 
 43 
    
 
DVWA Polymorphism Genotype A group n=20 %  HWE 
B group 
n=21 %  HWE  
C group 
n=20 %  HWE 
 rs11718863                     
TT WT 15 75   17 81   9 45   
TA H 4 20 0,33 4 19 0,63 10 50 0,39 
AA MUT 1 5   0 0   1 5   
rs7639618                     
GG WT 15 75   17 81   9 45   
GA H 4 20 0,33 4 19 0,63 10 50 0,39 
AA MUT 1 5   0 0   1 5   
rs7651842                     
AA WT 14 70   15 71,4   15 75   
AG H 6 30 0,43 5 23,8 0,51 4 20 0,33 
GG MUT 0     1 4,8   1 5   
rs7639807                     
GG WT 14 70   15 71,4   15 75   
GA H 6 30 0,43 5 23,8 0,51 4 20 0,33 
AA MUT 0     1 4,8   1 5   
rs17040821                     
CC WT 14 70   15 71,4   15 75   
CT H 6 30 0,43 5 23,8 0,51 4 20 0,33 
TT MUT 0     1 4,8   1 5   
HWE: Hardy Weinberg 
Equilibrium                     
n=number of patients                     
Table 11 Genetic analysis results according to KL grading 
 
 
KL and genotype association analysis 
To evaluate a potential association between genotypes, WT group or 
Mutated (Mut + H) one and the KL groups (A, B, C), Mann Whitney-
U test, Chi-Square test and Fisher’s exact test were performed (Table 
4). Analysis showed a statistically significant association between 
genotype and KL grading scale for the rs11718863 and rs7639618 
DVWA polymorphisms (p = 0.03). These results are in line with the 
study of Valdes AM et al (65), where these polymorphisms are 
associated with the risk of knee OA in the UK population, but to our 
knowledge, this is the first study that reports the simultaneous 
presence of these two genetic alterations associated with KL in a 
Sicilian group. Finally, it is possible to note in Table 4, that 
rs11718863 and rs7639618 DVWA SNPs (genotype H + Mut) are 
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more represented in group C (55%), compared to the other two 
groups A (25%) and B (19%), suggesting that they can be associated 
with a more severe OA radiographic grade. 
For rs7651842, rs7639807 and rs17040821 DVWA SNPs, we did not 
observed significant statistical association with radiographic KL 
grade (Table 12).  
 
 
 
  KL and Genotype   KL and Alleles 
DVWA 
Polymorphism   WT % H/Mut % 
p-
value*   
Allele 
T % 
Allele 
A % 
p-
value* 
rs11718863 
A 15 75 5 25   A 34 85 6 15   
B 17 81 4 19 0,03 B 38 90,5 4 9,5 0,04 
C 9 45 11 55   C 28 70 12 30   
                Allele 
G   
Allele 
A   
  
 rs7639618 
A 15 75 5 25   A 34 85 6 15   
B 17 81 4 19 0,03 B 38 90,5 4 9,5 0,04 
C 9 45 11 55   C 28 70 12 30   
                Allele A   
Allele 
G 
    
rs7651842 
A 14 70 6 30   A 34 85 6 25   
B 15 71,4 6 28,6 0,936 B 35 83,3 7 16,7 0,9713 
C 15 75 5 25   C 34 85 6 25   
                Allele 
G   
Allele 
A   
  
 rs7639807 
A 14 70 6 30   A 34 85 6 25   
B 15 71,4 6 28,6 0,936 B 35 83,3 7 16,7 0,9713 
C 15 75 5 25   C 34 85 6 25   
                Allele 
C   
Allele 
T   
  
rs17040821 
A 14 70 6 30   A 34 85 6 25   
B 15 71,4 6 28,6 0,936 B 35 83,3 7 16,7 0,9713 
C 15 75 5 25   C 34 85 6 25   
* Chi-Squared Test                       
Table 12 Genotype and alleles statistical association with KL grade 
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Synovial fluid Cytokines assay result 
Table 13 shows the quantities of cytokines, chemokine and grow 
factor measured in the synovial fluid of each patients knee joint  
 
 
 Hu IL-6  
Hu IL-
7  Hu IL-8  Hu IL-10 
Hu IL-
12(p70) Hu IL-13 
Hu 
GM-
CSF  
Hu 
MCP-1  
Hu 
MIP-
1b  
Hu 
TNF-a 
Sample 
 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
Conc in 
Range 
1 32,65 3,36 22,6 2,32 1,92 1,94 59,91 394,1 161,2 0,55 
2 39,68 4,37 6,9 3,64 OOR < 4,8 13,5 96,0 53,86 OOR < 
3 2655,08 2,38 22,84 7,16 11,17 1,17 127,28 138,4 173,1 18,2 
4 33,7 3,09 22,08 3,88 6,99 2,07 73,87 398,31 162,8 0,68 
5 40,53 4,44 6,39 3,64 0,9 5,74 15,5 92,33 55,08 OOR < 
6 2529,01 3,15 22,74 9,39 8,15 1,53 131,73 150,53 172,3 18,69 
7 1546 5,35 50,73 11,53 5,2 1,98 49,11 225,68 133,6 3,69 
8 1596,19 5,5 51,1 11,12 6,43 1,25 50,16 229,17 138,6 3,66 
9 83,61 7,67 25,92 OOR < 4,18 3,63 16,35 224,68 216,4 0,6 
10 102,45 3,74 17,25 2,32 9,64 4,36 25,14 105,49 173,1 0,48 
11 733,67 4,13 19,6 4,52 3,9 0,98 36,81 151,53 149,0 2,68 
12 0,65 1,18 3,28 2,03 OOR < 3 8,56 22,07 8,5 OOR < 
13 1,3 2,13 4,68 2,71 9,42 0,86 OOR < 63,97 53,96 OOR < 
14 720,04 4,26 18,71 5,59 OOR < 1,04 82,78 141,03 60,36 2,31 
15 440,52 4,02 18,36 14,56 84,24 1,3 OOR < 192,87 166,0 0,86 
16 469,49 4,14 19,57 18,85 78,32 1,27 OOR < 205,08 172,4 1,17 
17 166,81 2,85 29,16 2,78 5,87 1,32 46,28 331,94 188,5 0,55 
18 2,64 8,89 12,21 3,23 OOR < 5,65 80,46 124,25 61,2 6,27 
19 4,78 2,85 6,59 3,84 2,98 0,99 15,03 122,05 57,93 0,93 
20 371,03 6,84 23,4 5,43 21,89 7,5 35,97 259,73 243,0 2,28 
21 377,39 7,08 20,97 5,27 14,15 8,08 37,73 250,21 240,1 2,38 
22 19,83 4,01 23,34 1,75 61,66 OOR < 6,48 146,23 126,6 0,77 
23 35,97 3,94 23,86 3,75 1,15 1,78 37,31 65,13 102,3 OOR < 
24 OOR < OOR < OOR < OOR < OOR < OOR < OOR < OOR < OOR< OOR < 
25 46,54 4,08 9,22 OOR < 5,82 2,14 4,07 117,7 170,9 OOR < 
26 124,69 2,56 12,06 2,49 1,86 2,53 OOR < 54,39 140,8 OOR < 
27 84,17 13,61 30,39 2,87 1,92 4,34 31,99 124,58 89,53 1,31 
28 1515,93 4,96 194,63 6,58 6,43 4,9 87,12 428,43 210,5 3,81 
29 15,48 4,87 9,78 3,12 OOR < 3,92 51,44 115,91 66,91 0,51 
30 180,42 OOR < 1316,43 22,94 139,76 3,23 21,3 410,7 217,5 3,37 
31 2244,31 2,67 868,19 71,27 69,87 3,15 196,59 185,77 98,47 44,21 
32 3069,94 2,1 3683,65 63,48 14,74 3,94 205,08 250,15 961,0 24,16 
33 113,73 4,08 24,13 0,94 OOR < 4,21 OOR < 161,62 160,2 OOR < 
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34 107,97 3,69 90,27 3,03 2,28 6,34 37,98 281,01 191 1,03 
35 107,86 3,81 89,09 3,43 2,92 5,5 32,93 284,66 184,9 0,89 
36 33,89 5,01 5,2 4,25 OOR < 3,43 61,7 207,01 45,85 0,53 
37 18 3,54 7,37 0,56 OOR < 0,46 32,59 141,56 142,7 OOR < 
38 310,93 3,77 19,9 6,43 4,75 8,15 15,41 262,38 184,5 2 
39 193,17 1,19 25,71 1,22 13,34 2,15 OOR < 143,05 125,1 1,07 
40 159,33 4,45 10,11 2,57 OOR < 5,76 16,72 171,38 110,5 OOR < 
41 515,84 4,49 49,64 2,33 10,19 4,94 44,98 301,77 133,7 1,59 
42 190,93 2,83 49,12 1,57 12,9 OOR < OOR < 170,51 313,5 0,39 
43 314,55 3,19 32,83 1,18 OOR < 6,45 28,72 120,15 52,59 0,41 
44 79,63 2,15 18,23 3,03 32,4 4,51 66,82 56,47 29,61 6,34 
45 167,66 4,65 13,57 0,49 OOR < 1,64 38,81 167,45 108,2 0,77 
46 1079,31 3,4 116,48 0,75 OOR < 0,88 19,49 87,03 95,52 2,9 
47 530,5 3,46 39,85 OOR < OOR < 2,35 45,15 184,35 94,91 0,93 
48 1565,55 4,01 91,13 21,94 200,92 3,3 32,84 215,65 105,1 4,73 
49 40,5 4,6 17,6 1,75 2,74 1,52 OOR < 69,62 180,6 OOR < 
50 219,76 2,16 141,74 3,14 13,71 1,35 23,19 88,16 304,1 6,07 
51 55,68 3,54 8,08 OOR < 0,65 1,04 11,07 29,82 168,7 OOR < 
52 613,97 5,44 44 2,46 13,07 3,27 44,9 158,75 252,4 1 
53 748,86 5,63 35,28 4,49 10,51 3,28 57,47 72,85 227,3 2,21 
54 1340,41 4,86 1506,94 11,25 86,24 1,88 OOR < 75,75 380,2 4,71 
55 28,5 4,71 25,02 2,42 3,49 6,07 37,06 130,79 160,9 OOR < 
56 1624,04 4,5 20,12 5,41 1,92 3,23 22,92 556,04 158,4 3,69 
57 968,99 6,97 82,45 3,14 12,04 4,9 32,76 338,95 217,0 2,88 
58 1725,25 1,72 136,93 2,96 6,71 4,78 43,19 221,15 161,8 7,64 
59 1602,13 5,31 20,53 4,63 5,43 4,3 33,61 518,23 165,0 4,55 
60 197,04 4,95 15,02 0,64 17,63 3,27 30,02 118,02 103,3 0,89 
Hu IL-1b  Hu IL-2  Hu IL-4  Hu IL-5  Hu IL-17  Hu G-CSF  Hu IFN-g 
are Out of Range (OOR) 
	   	   	   	   
Table 13 Synovial fluid analysis. Concentration of Cytokines 
 
Measurable levels of cytokines were not detected in all samples. 
Among the panel of 17 cytokines, Hu IL-1b, Hu IL-2, Hu IL-4, Hu 
IL-5, Hu IL-17, Hu G-CSF and Hu IFN-g are Out of Range (OOR) 
and for these reason excluded from the analysis. 
Samples are divided into three groups, related to K&L classification, 
-group A, from 1 to 20, early OA, grade 1-2 
-Group B from 21 to 41, medium OA, grade 3  
-Group C from 42 to 60, late OA, grade 4 
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In order to better analyse the relation between knee joint 
inflammation and immune modulation and K&L grade, the cytokines 
levels were compared among the three groups, using the Mann–
Whitney tests. Table 14 reports   the medians of cytokines levels for 
each K&L group, , and the Mann-Whitney test’ results for the 
comparisons studied (A vs B; B vs C; A vs C)  P≤0.05 was accepted 
as statistically significant. 
 
 
Analytes 
(pg/ml) 
Hu 
IL-6  
Hu 
IL-7  
Hu 
IL-8  
Hu 
IL-10 
Hu IL-
12(p70) 
Hu 
IL-13 
Hu 
GM
CSF  
Hu MCP-
1(MCAF)  
Hu 
MIP-
1b  
Hu 
TNF-a 
Group A 134,6 4,1 19,6 3,9 6,7 1,7 46,3 151,0 155,1 1,7 
Group B  119,2 4,0 24,0 3,1 6,4 3,9 37,3 178,6 141,8 1,5 
Group C 530,5 4,5 35,3 3,0 12,0 3,3 33,2 130,8 161,9 2,9 
  
         
  
MANN 
WHITNEY  
(p-value) 
Hu 
IL-6  
Hu 
IL-7  
Hu 
IL-8  
Hu 
IL-10 
Hu IL-
12(p70) 
Hu 
IL-13 
Hu 
GM
CSF  
Hu MCP-
1(MCAF)  
Hu 
MIP-
1b  
Hu 
TNF-a 
A vs B 0,92 0,94 0,07 0,27 0,98 0,01 0,76 0,38 0,47 0,85 
B vs C 0,04 0,84 0,53 0,31 0,63 0,18 0,79 0,18 0,68 0,57 
A vs C 0,13 0,70 0,01 0,03 0,36 0,17 0,34 0,36 0,29 0,49 
  
         
  
A vs BC 0,35 0,79 0,01 0,06 0,58 0,02 0,47 0,19 0,30 0,59 
           
Table 14 Medians of analytes measured divided in Group A - B - C 
  
Moreover, in order to evaluate differences between early OA and late 
OA, the Mann-Withney test has been applied between the A group vs 
the BC group.  
In our patients cohort, an unbalanced and enhanced knee joint 
inflammation can be observed to be related with the grading 
progression. Indeed, a trend  for the increasing of inflammatory 
molecules such as IL-6, TNF-α, IL-12, IL-8 together to the 
decreasing of IL-10 levels can be described toward A vs C K&L 
grading. 
Taking together these results justify and sustain the role of 
inflammation in the disease progression.  
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Particularly, the significant different comparisons were:   the Hu IL-6 
values in the B versus C group;  the Hu IL-8, also known as 
chemokine CXXL8,  in the A versus C group and A vs BC groups; , 
the Hu IL-10 in the A versus C group; the Hu IL-13 in the A versus B 
group and in A vs BC groups.  
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DISCUSSION 
Pathological changes that occur with OA are loss of cartilage, 
osteophytes, subchondral sclerosis and cysts and deformation of the 
bone. Soft tissue, such as ligaments, can also be affected. The 
articulation object of our study is the knee, both because it’s the most 
affected joints and for numerous diagnostic tests available. These 
features make the knee joint ideal for clinical, radiographic and 
proteogenomic studies. 
Genetic and biochemical analyses have been developed to evaluate 
disease progress and severity, allowing a non radiographical 
alternative for an early detection of osteoarthritis or, linked by K&L 
grading, to better define the pathology.  
The aim of our pilot study was to update the knee OA grading with 
further clinical and genetic associated data, since OA is nowadays 
considered a polygenic and multifactorial disease (69). 
We studied the possible association between KL grade, clinical 
features (AKSS, age), susceptibility polymorphisms and cytokines 
expression to OA, in order to better define the grading of this 
disorder. 
In our cohort of 66 patients, a statistical association was observed 
between the variables analysed: KL data versus: KS, FS, age. In 
particular, statistical association between KL grade versus KS and FS 
showed that KL group A can be associated with a medium clinical 
score, while KL group B and KL group C are related with low KS 
and FS. This suggests that a mild to severe OA radiographic grade is 
linked to severe clinical conditions and loss of articular function. In 
addition, association analysis between KL grade and age of patients 
confirms that severity of symptoms increases with age: the majority 
of our patients with KL grade A were 54 to 65 years old, and most of 
the patients with grade C were 65 to 86 years old. 
Concerning the mutational analysis, we genotyped the patients for 
FRZB (OS1A and OS1B), MATN3 (OS2), PTHR2 (OS3), ASPN 
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D14 (OS4), GDF5 (OS5) and DVWA (OS6). Results revealed a 
significant statistical association between KL grade and GDF5 
rs143383 (OS5) and DVWA rs11718863 (OS6) genetic alterations. 
The OS5 rs143383 polymorphism, localized in the 5′-untranslated 
region, causes a decrease in the transcriptional activity of GDF5 and 
is still the most robustly replicated polymorphism associated with 
OA. This gene encodes growth differentiation factor 5, a bone 
morphogenic protein involved in the development, homeostasis and 
repairing of the bone, cartilage and other articular tissues (70). The 
Sicilian OA patients’ odds ratio of 1.53 (confidence interval, 1.11 to 
2.11) describes a positive association between rs143383 GDF5 and 
KL (KL ≤2 vs. KL > 2), a trend in line with other studies  [48]. 
Moreover, even if our cohort isn’t larger than other, the data are 
comparable for the variables analysed, supporting this variant as an 
OA progression marker. 
The OS6 rs11718863 polymorphism is localized in an exonic region 
of the DWVA gene and causes a missense mutation (71). The 
DWVA protein, interacts with β-tubulin of microtubules and has an 
important role in the regulation of chondrocyte differentiation, 
protecting articulate joints from OA onset. In particular, the OS6 
rs11718863 SNP induces a decreasing interaction between DVWA 
and β-tubulin  (72-73).  
In studied patients cohort, this genetic alteration was more 
represented in the KL group C (55%) compared with the other 
groups, KL group A (25%) and KL group B (19%), respectively. 
Therefore, it is possible to suggest that OS6 can be associated with a 
more severe OA radiographic grade, displaying its predictive role as 
OA marker progression. 
Concerning the rs11718863 (OS6) and rs7639618 DVWA genetic 
polymorphisms, alleles frequencies analyzed were different in the 
Sicilian group with respect to those reported in dbSNP database for 
European individuals of various geographic areas.  
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In line with data obtained by other researchers (65), the minor allele 
frequency (MAF) for these SNPs were much lower in the European 
samples than in other ones. In addition, for the two above-mentioned 
genetic alterations, MAF values were greater in the Sicilian 
individuals than in the European ones: 18% rather than 14.6% and 
13%, according to data reported by colleagues and in SNPs database 
respectively (52). 
Moreover, a perfect genotypic correspondence in all individuals 
investigated (100% of the cases – 161 patients) has been displayed in 
between rs11718863 and rs7639618 DVWA SNPs. All individuals 
are double WT or double H or double MUT carriers. Linkage 
Disequilibrium Analysis was performed in order to verify the degree 
of allelic segregation among these SNPs. The r2 test suggests that 
rs11718863 and rs7639618 DVWA SNPs  segregate as haplotype, 
according to the observation of a coinheritance of SNP alleles.  
(r2 = 1) (Figure 14).  Considering that rs11718863 DVWA SNP is 
marked as susceptibility site, and that it is in LD with rs7639618 
DVWA, we suggest to assay also this genetic alteration in OA 
patients in order to define the functional role of DVWA in OA 
grading and progression.  
In addition, even for rs7651842, rs7639807 and rs17040821, 
sequencing data analysis have displayed a perfect genotypic 
correspondence (100% of the cases) in all of the 161 individuals 
investigated. In other words, all individuals were triple WT or triple 
H or triple MUT carriers. Interestingly, three of the 161 individuals 
investigated were triple MUT, also taking into consideration that in 
the literature data these genotypes occur separately at low 
percentages (rs7651842: 0.9%; rs7639807: 1.7%; rs17040821:1.7%). 
Therefore, we calculated r2 LD coefficient, using a pairwise approach 
which resulted r2 = 1 in every SNP pair analyzed, suggesting that the 
above-mentioned SNPs segregate as haplotype (Figure 1).  
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In order to extend the association with KL grade also for the 
rs7639618 DVWA SNP, we tested the significance of rs7639618 
allele dose distribution among the KL OA groups showing a 
significant association between rs7639618 and KL in our OA patients 
cohort. Sequencing analysis of the electropherograms revealed the 
presence of other three less known DVWA SNPs: rs7651842, 
rs7639807 and rs17040821, for which no literature data were 
available. Also for these SNPs, MAF values were approximately 
three fold greater in the Sicilian individuals than in the European 
ones. Unlike rs11718863 and rs7639618, these polymorphisms are 
not marked as clinically relevant in dbSNP database probably due to 
absence of bibliographic data. These three genetic alterations are 
located in the same exonic region of DVWA gene and for this reason 
it is possible to hypothesize that they could cause protein functional 
changes, not still investigated.  
Therefore, in this study a high percentage of the 161 Sicilian 
individuals are carriers of DVWA SNPs mutated alleles. In 
particular, 29.8% were H or homozygous MUT for rs11718863 
(OS6) and rs7639618, whereas, 19.9% were H or homozygous MUT 
for rs7651842, 7639807 and rs17040821 SNPs. 
Finally, as inflammation is increasingly being considered as an 
important component of OA’s pathophysiology, cytokines are being 
assessed as possible candidates for biochemical markers. 
Biochemical analyses have been developed to evaluate disease 
progress and severity, allowing a non radiographical alternative for 
an early detection of osteoarthritis. (74-76).  Grouping appropriate 
cytokine markers together and assessing them collectively with other 
markers as well as K&L provide a more statistically powerful tool in 
research and clinical applications, and additionally aid in 
distinguishing between early and late OA. Synovial fluid (SF) 
reflects the biological milieu of the joint and offers a direct measure 
of joint pathophysiology representing an important potential source 
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of biomarkers in osteoarthritis (63). Furthermore, the OA joint 
viscosity is greater than that of inflamed joints. 
In our patient cohort, an unbalanced and enhanced knee joint 
inflammation can be observed to be related with the grading 
progression. Indeed, a trend  for the increasing of inflammatory 
molecules such as IL-6, TNF-α, IL-12, IL-8 together to the 
decreasing of IL-10 levels can be described toward A vs C K&L 
grading. 
IL-6 is a glycoprotein consisting of 184 amino acid residues (77)  that 
strongly activates the immune system and enhances inflammatory 
response and it may be classified as pro-inflammatory cytokine. The 
increased concentration of IL-6 is present in synovial fluid, with an 
high level in Group C and is positively correlated with the intensity 
of lesions in X-ray imaging (78-80).  
IL-8, also known as CXXL8, is a potent chemokine in the immune 
system. Few studies have examined this chemokine in synovial fluid 
and its relationship with OA. IL-8 is a key mediator associated with 
inflammation, classified as pro-inflammartory cytokine. IL-8 
secretion is increased by oxidant stress, causing the recruitment of 
inflammatory cells and inducing a further increase in oxidant stress 
mediators. In this study, IL-8 can be suggested as a good progression 
marker to better define OA grading (78).  
IL-13 has an anti-inflammatory and chondoprotective effects. It is 
well documented its capacity to transfer the intracellular signal both 
by the cascade JAK2/STAT3 and IL-13R𝛼1/TYK2/STAT1/STAT6. 
Literature results indicate the potential utility of IL-13 in the 
treatment of OA, as a compound that inhibits the inflammatory 
processes, protects chondrocytes, reduces the secretion of 
inflammatory cytokines and metallo-proteinases, while stimulating 
the synthesis of IL-1Ra. In agreement with its protective role, in this 
study, the IL-13 is the only cytokine, having an anti-inflammatory 
role, which significantly increases passing from the A versus B and C 
groups of the K&L grading (81).  
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On the other hand, the major anti-inflammatory cytokine,  
Interleukin-10 (IL-10), which  also have a chondoprotective effect 
and is also involved in stimulating the synthesis of type II collagen 
and aggrecan, in our study, it does not seem to increase adequately to 
the disease progression (82). 
However,  IL-10 contribute to the suppression of the inflammation of 
the synovial membrane (83-84). By reducing inflammation, these 
mediators can support cartilage production acting as anabolic 
effectors which can slow the progress of OA. 
In our study, the IL-10 expression is progressively reduced going 
from A vs C group. Results of studied cohort show differential 
expression among A group vs C group, showing also in this cases a 
possible target to distinguish between early and late OA.  
Summarized,  nonetheless large scale studies are necessary to asses 
the effectiveness of these biomarkers, some inflammatory molecules 
could  represent potential prognosis OA biochemical markers . 
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Conclusion 
This work represents a multidisciplinary and translational medicine 
approach to study OA where clinical, radiographic, genetic and 
biochemical evaluation could contribute to better define the disease 
grading and progression for the development of new therapies. 
The statistically significant association between clinical, radiographic 
and genetic signs observed suggests the extension of the actual 
grading of knee OA based mainly on X-ray features. Moreover, 
research using a similar multiplex ELISA approach or other 
proteomic techniques may enable researchers and clinicians to 
develop more accurate biochemical profiles of synovial fluid to help 
diagnose OA, identify subsets of OA or individual characteristics, 
guide clinical decisions, and identify patients at risk for OA after 
knee injury. (Figure 15) 
 
 
Figure 15 Model of relation between KL grading groups and selected 
features described in the study. 
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